期刊文献+

ABCG4和V-ATPase在非小细胞肺癌中的表达及相关性临床意义 被引量:1

The expression of ABCG4,V-ATPase and clinic significance of their correlation with NSCLC
下载PDF
导出
摘要 背景与目的多药耐药是肺癌化疗治疗失败的重要原因,ABC介导药物外排是耐药的主要因素,寻找该家族中新的耐药蛋白并阐明其耐药机制十分重要。ABCG4有望成为耐药候选基因;耐药性与细胞内外pH值可能有关,而V-ATPase在调节pH值起主要作用。本研究通过检测ABCG4和V-ATPase在非小细胞肺癌中的表达,分析其与病理分级和TNM分期间的关系以及两蛋白表达的相关性,为研究ABCG4、V-ATPase在肿瘤表达及耐药相关性提供基础。方法采用免疫组化EnVinsion法、免疫荧光法检测在肺鳞癌、腺癌中的表达,激光共聚焦显微镜观察其定位和共定位,用统计学分析表达差异性和相关性。结果ABCG4在肺鳞癌、腺癌中高表达,两者差异性显著(P=0.001);鳞癌Ⅱ和Ⅱ-Ⅲ组间、腺癌不同分化组间差异性显著;鳞癌和腺癌TNM分期秩和检验差异性显著。V-ATPase在鳞癌、腺癌中也为高表达,两者差异性非常显著;鳞癌Ⅱ和Ⅱ-Ⅲ组间、腺癌不同分化组间差异性显著;在鳞癌和腺癌TNM分期秩和检验差异性均不显著。ABCG4和V-ATPase蛋白在鳞癌、腺癌、鳞癌Ⅱ和Ⅱ-Ⅲ、中分化腺癌各组中的表达相关性检验P<0.01,相关系数rs分别为0.771、0.765、0.714、0.777、0.865;而低分化腺癌组中的相关性检验P值为0.048,相关系数rs为0.350。ABCG4主要定位在胞膜上和胞质中,两蛋白有共定位现象。结论ABCG4和V-ATPase在非小细胞肺癌中高表达,表达的高低与病理分级、TNM分期有关;两蛋白在鳞癌、腺癌及其分级间表达都存在相关性,可能存在相互作用的现象。这为研究ABCG4和V-ATPase在肿瘤中的表达及可能耐药作用提供了实验依据。 Background and objective It has been proven that the multiple drug resistance is main reason for failure of chemotherapy in lung cancers and ABC transporter play a main role for chemoresistance in mediating drug efflux.So searching for new drug resistant protein of the ABC family and elucidating its resistant mechanism is very important.ABCG4 is one of ABC family and is expected to be candidate drug resistant protein;and the drug resistance probably correlated with pH value around cancer cell,while,V-ATPase...
出处 《中国肺癌杂志》 CAS 2008年第5期691-695,共5页 Chinese Journal of Lung Cancer
基金 陕西省攻关基金(No.2004K13-G7)资助~~
关键词 肺肿瘤 ABCG4 V-ATPASE 耐药蛋白 Lung neoplasma ABCG4 protein V-ATPase Drug resistance
  • 相关文献

参考文献2

二级参考文献13

  • 1Kreisholt J,Sorensen M,Jensen PB,et al.Immunohistochemical detection of DNA topoisomerase Ⅱ alpha,P-glycoprotein and mul tidrug resistance protein (MRP) in small-cell and non-small-cell lung cancer.Br J Cancer,1998,77(9):1469-1473.
  • 2Tan B,Piwnica-Worms D,Ratner L.Multidrug resistance transporters and modulation.Curr Opin Oncol,2000,12(5):450-458.
  • 3Arai T,Yasuda Y,Takaya T,et al.Immunohistochemical expression of glutathione transferase-pi in untreated primary non-smallcell lung cancer.Cancer Detect Prey,2000,24(3):252-257.
  • 4Nishio K,Nakamura T,Koh Y,et al.Drug resistance in lung cancer.Curr Opin Oncol,1999,11(2):109-115.
  • 5Berger W,Elbling L,Hauptmann E,et al.Expression of the multidrug resistance-associated protein (MRP) and chemoresistance of human non-small-cell lung cancer cells.Int J Cancer,1997,73(1):84-93.
  • 6Scheper RJ,Broxterman HJ,Scheffer GL,et al.Overexpression of a M(r) 110,000 vesicular protein in non-P-glycoprotein-mediated multidrug resistance.Cancer Res,1993,53(7):1475-1479.
  • 7Chauncey TR.Drug resistance mechanisms in acute leukemia.Curr Opin Oncol,2001,13(1):21-26.
  • 8Oshika Y,Nakamura M,Tokunaga T,et al.Multidrug resistance-associated protein and mutant p53 protein expression in nonsmall cell lung cancer.Mod Pathol,1998,11(11):1059-1063.
  • 9Schroeijers AB,Scheffer GL,Reurs AW,et al.Detection of the Mr 110,000 lung resistance-related protein LRP/MVP with monoclonal antibodies.J Histochem Cytochem,2001,49 (11):1379-1385.
  • 10Trussardi A,Poitevin G,Gorisse MC,et al.Sequential overexpression of LRP and MRP but not P-gp 170 in VP16-selected A549 adenocarcinoma cells.Int J Oncol,1998,13(3):543-548.

共引文献10

同被引文献3

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部